Form 4: Corvus Director Thompson Granted 15,000 Stock Options

Corvus Pharmaceuticals director and 10% owner Peter A. Thompson was granted 15,000 stock options with an exercise price of $11.6.

Summary

• Peter A. Thompson, a Director and 10% Owner of Corvus Pharmaceuticals, Inc. (CRVS), was granted 15,000 stock options.
• The options have an exercise price of $11.6 per share.
• The grant date for these options was June 11, 2026, and they expire on June 11, 2036.
• The options vest 100% on the earlier of the first anniversary of the grant date (June 11, 2027) or the date of the 2027 Annual Meeting of stockholders, contingent on continuous service.
• Thompson disclaims beneficial ownership of these securities, as he is obligated to transfer them or their economic benefit to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC for OrbiMed Private Investments V, LP.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard director compensation and continued alignment of a significant owner (via OrbiMed) with the company's long-term prospects, though the beneficial ownership disclaimer is a nuance.

Positives

• The grant of stock options to a director and 10% owner aligns management and significant shareholder interests with long-term company performance.
• The vesting schedule encourages continued service and commitment from a key stakeholder.

Negatives

• The reporting person disclaims beneficial ownership, indicating the economic benefit flows to OrbiMed Private Investments V, LP, which might dilute the direct incentive for Peter A. Thompson as an individual.

Risks

• The value of the stock options is contingent on the future stock price of Corvus Pharmaceuticals exceeding the exercise price of $11.6.
• The vesting is conditional on continuous service, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

This filing does not contain explicit forward-looking statements or guidance regarding the company's performance or strategy, beyond the vesting conditions for the options.

Industry Context

StockSavvy.ai notes that stock option grants are a standard component of executive and director compensation packages in the biotechnology and pharmaceutical industries, aiming to align leadership incentives with shareholder value creation. The involvement of OrbiMed, a prominent healthcare investment firm, through its affiliates, highlights its continued influence and strategic interest in Corvus Pharmaceuticals.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The exercise price of $11.6, if it represents the fair market value on the grant date, is standard for incentive options.
• The 100% vesting on the earlier of one year or the next annual meeting is a relatively quick vesting schedule for a director grant, often seen to ensure immediate alignment and retention. Specific comparable companies or projects are not mentioned in the filing to allow for a direct comparison of the size of the grant, but the structure is typical.

Related Party Transactions

• Peter A. Thompson, as a Director and 10% Owner, is obligated to transfer the economic benefits of these options to OrbiMed Private Investments V, LP, through OrbiMed Advisors LLC and OrbiMed Capital GP V LLC. This indicates a pre-existing arrangement related to his role and investment firm affiliations.

Stakeholder Impact

• Shareholders: The grant of options could be seen as a positive for aligning director interests, but the eventual exercise would lead to minor dilution. The disclaimer of beneficial ownership by Thompson means the direct incentive is for OrbiMed, a major shareholder.

Next Steps

• Continued service by Peter A. Thompson as a director until the vesting date.
• Potential exercise of the options by OrbiMed Private Investments V, LP, if the stock price exceeds the exercise price after vesting.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director and 10% owner, Peter A. Thompson, whose economic benefit is directed to OrbiMed Private Investments V, LP. While it signifies continued alignment of a major stakeholder with Corvus Pharmaceuticals' long-term performance, it does not provide new fundamental information about the company's operational or financial health that would warrant a change in investment stance. It's a standard compensation event rather than a catalyst for significant price movement.

Keywords

Corvus Pharmaceuticals, CRVS, Stock Options, Form 4, Insider Transaction, Director Compensation, OrbiMed, Beneficial Ownership